Fox Run Management L.L.C. Makes New $111,000 Investment in Cryoport, Inc. (NASDAQ:CYRX)

Fox Run Management L.L.C. acquired a new stake in shares of Cryoport, Inc. (NASDAQ:CYRX) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 14,314 shares of the company’s stock, valued at approximately $111,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of CYRX. Avanza Fonder AB acquired a new position in Cryoport during the 4th quarter valued at approximately $64,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cryoport during the third quarter valued at $82,000. Intech Investment Management LLC acquired a new position in shares of Cryoport in the 3rd quarter valued at $105,000. Olympiad Research LP purchased a new position in Cryoport in the 4th quarter worth $103,000. Finally, Heritage Investors Management Corp acquired a new stake in Cryoport during the 4th quarter worth about $122,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Stock Down 2.4 %

Cryoport stock opened at $6.09 on Friday. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $20.11. The firm has a market cap of $303.95 million, a price-to-earnings ratio of -1.80 and a beta of 1.67. The business’s 50-day moving average price is $6.68 and its 200 day moving average price is $7.32. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. As a group, sell-side analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a report on Wednesday, March 5th. UBS Group upgraded Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Monday, March 24th. Finally, Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $11.67.

Insider Activity at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now owns 765,399 shares in the company, valued at approximately $4,814,359.71. This represents a 0.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 19,830 shares of company stock worth $118,353 in the last 90 days. Corporate insiders own 10.10% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.